Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Scientists engineer therapeutic system with two arms to get better hold on cancer target

Scientists engineer therapeutic system with two arms to get better hold on cancer target

Advances in head and neck cancer treatments: an interview with Prof. Argiris

Advances in head and neck cancer treatments: an interview with Prof. Argiris

Novel conjugate therapy shows promise in destroying ALL cells with few side effects

Novel conjugate therapy shows promise in destroying ALL cells with few side effects

Texas Biomed scientists receive $23 million NIH grant to develop AIDS vaccine

Texas Biomed scientists receive $23 million NIH grant to develop AIDS vaccine

Adding new monoclonal antibody to chemotherapy improves survival in soft-tissue sarcoma patients

Adding new monoclonal antibody to chemotherapy improves survival in soft-tissue sarcoma patients

Researchers develop antibody with potential therapeutic effects against multiple sclerosis

Researchers develop antibody with potential therapeutic effects against multiple sclerosis

Researchers identify novel therapeutic monoclonal antibodies from Zika-infected patients

Researchers identify novel therapeutic monoclonal antibodies from Zika-infected patients

Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

Study finds evidence that PD-1 antibody may benefit men with metastatic prostate cancer

H3N2v-neutralizing antibodies produced from human subjects given candidate vaccine

H3N2v-neutralizing antibodies produced from human subjects given candidate vaccine

Necitumumab drug shows minor added benefit in patients with metastatic NSCLC

Necitumumab drug shows minor added benefit in patients with metastatic NSCLC

Celltrion Healthcare commits to develop lab tests for evidence-based decision-making in anti-TNF treatment

Celltrion Healthcare commits to develop lab tests for evidence-based decision-making in anti-TNF treatment

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

Novel anti-interleukin 1-alpha antibody shows promise in treating advanced colorectal cancer patients

Novel anti-interleukin 1-alpha antibody shows promise in treating advanced colorectal cancer patients

Novel therapeutic approach may be effective for disrupting bacterial biofilms

Novel therapeutic approach may be effective for disrupting bacterial biofilms

Switch to rituximab shows anti-inflammatory effect in relapsing-remitting MS

Switch to rituximab shows anti-inflammatory effect in relapsing-remitting MS

FDG-PET imaging tracks ability of atezolizumab to bolster immunity against NSCLC

FDG-PET imaging tracks ability of atezolizumab to bolster immunity against NSCLC

Dr. Pinchas Tsukerman earns prestigious Kaye Innovation Award for research on cancer immunotherapy

Dr. Pinchas Tsukerman earns prestigious Kaye Innovation Award for research on cancer immunotherapy

Study provides insights into new pathways to generate universal vaccine against influenza viruses

Study provides insights into new pathways to generate universal vaccine against influenza viruses

Migraine drug has quick onset of action

Migraine drug has quick onset of action

IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

IQWiG examines whether ramucirumab drug offers added benefit for MCRC and NSCLC patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.